Many existing drug compounds as well as those coming out of discovery are poorly soluble and need special efforts to be formulated into drug products. Depending on the therapeutic area, as many as 80% of new drugs are classified as poorly soluble. The development of poorly soluble molecules pose significant challenges in product design and development and can delay the launch of the product. Several approaches can be taken to address the poor solubility of the molecules and how one can increase the solubility and bioavailability. Some of the practical approaches that may be adopted by the formulation scientist are:
- Alternative salt forms
- Metastable crystalline polymorphic forms
- Complex formation
- Solubilization by surfactants
- Amorphous forms
- Increasing specific surface area
- Nanotechnology based approaches
The second annual conference on Formulation and Drug Delivery, May 21-22, Boston, MA will discuss effective formulation and delivery technologies for enhancing solubility and bioavailability. Key opinion leaders and top pharmaceutical scientists will share their case studies on what strategies they adopted to develop poorly soluble drugs into scientifically sound, patient-centric formulations, and reducing their product development timelines.
- Hear Case Studies from AstraZeneca, BMS, Cempra, Cubist, Merck, Novartis, Pfizer and More!
- Learn Strategies on Improving Bioavailability, Preformulation, Risk Assessment & Mitigation
- Apply Enabling Technologies for Enhancing Solubility and Delivery
- Gain Knowledge on How to Reduce the Formulation & Process Development Timelines
- Participate in Interactive Short Course on Nanotechnology for Enhancing Bioavailability of Poorly Soluble
A focused short course on Nanotechnology for Enhancing Bioavailability of Poorly Soluble Drugs is also available, and offer detailed and in-depth discussions on Nanotechnology application (separate registration required).
Topics to be covered:
- Amorphous dispersions and polymeric nanoparticulates
- Liquid dispersions, especially, lipid and surfactant based self emulsifying
- Nano-emulsifying systems (SEDDS/SNEDDS)
- Excipients’ role in design of robust dispersive systems and maintaining supersaturation
- Effects of particle size on API stability and performance
- Navnit Shah, Ph.D., President & CSO, Kashiv Pharma
- Lipa Shah, Ph.D., Principal Scientist, Chemical and Pharmaceutical Profiling, Novartis Institutes for BioMedical Research, Inc.
- Michael Perlman, Ph.D., Senior Scientist II, Millennium Pharmaceuticals
- Salin Gupta Patel, Ph.D., Associate Principal Scientist, Nanoparticles Technology Development Team Lead, Merck Research Labs
- Shaukat Ali, Ph.D., Technical Support Manager, BASF Corp
For full details please visit WorldPharmaCongress.com/Formulation-Drug-Delivery. An exclusive discount of $200 is being offered to Lab-Training.com associates – simply enter priority keycode LT200 upon registration to receive your discount. This offer is non-transferrable and cannot be combined with other offers. Register by February 21 for best value!